Ocular Therapeutix
(NASDAQ) OCUL
Ocular Therapeutix Financials at a Glance
Market Cap
$2.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$52.04M
Net Income (TTM)
-$290.50M
EPS (TTM)
-$1.46
P/E Ratio
-7.05
Dividend
$0.00
Beta (Volatility)
1.48 (Average)
Dividend
$0.00
Beta (Volatility)
1.48 (Average)
Price
$10.25
Volume
102,728
Open
$10.21
Price
$10.25
Volume
102,728
Open
$10.21
Previous Close
$10.25
Daily Range
$9.92 - $10.43
52-Week Range
$6.23 - $16.44
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
1.48 (Average)
Price
$10.25
Volume
102,728
Open
$10.21
Previous Close
$10.25
Daily Range
$9.92 - $10.43
52-Week Range
$6.23 - $16.44
Estimated Earnings Date
Aug 4, 2026
OCUL News
OCUL: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Ocular Therapeutix
Industry
Pharmaceuticals
Sector
Health CareEmployees
325
CEO
Pravin U. Dugel, MD
Website
www.ocutx.comHeadquarters
Bedford, MA 01730, US
OCUL Financials
Key Financial Metrics (TTM)
Gross Margin
87.24%
Operating Margin
-575.42%
Net Income Margin
-558.24%
Return on Equity
-64.55%
Return on Capital
-36.78%
Return on Assets
-39.66%
Earnings Yield
-14.18%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
218.96M
Volume
102.73K
Avg. Volume
2.98M
Financials (TTM)
Gross Profit
$45.40M
Operating Income
-$299.44M
EBITDA
-$274.24M
Operating Cash Flow
-$226.21M
Capital Expenditure
-$14.74M
Free Cash Flow
-$240.94M
Cash & ST Invst.
$666.70M
Total Debt
$79.46M
Ocular Therapeutix Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$10.79M
+0.8%
Gross Profit
$9.46M
+0.2%
Gross Margin
87.68%
N/A
Market Cap
$2.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$8.21M
N/A
Employees
274
N/A
Net Income
-$88.61M
-38.3%
EBITDA
-$84.55M
-40.7%
Quarterly Fundamentals
Total Cash
$666.70M
+90.7%
Total Debt
$79.46M
+4.2%
Accounts Receivable
$24.35M
-3.5%
Inventory
$3.74M
+14.3%
Long Term Debt
$76.29M
+3.0%
Short Term Debt
$3.17M
+47.0%
Return on Assets
-39.66%
N/A
Return on Invested Capital
-43.72%
N/A
Free Cash Flow
-$70.66M
-51.6%
Operating Cash Flow
-$65.99M
-47.7%